Meiji

GSK’s says depot HIV injection works over three years

The new data, from the second of three pivotal trials intended to support a marketing application in Japan, showed that the drug was as effective as intravenous treatment with long-acting ... GSK says it remains on track to file for approval of

Roche’s new flu pill Xofluza approved in US

Discovered and developed by Shionogi, the drug is already approved in Japan, with Roche holding the marketing rights outside Japan and Taiwan.

China: AstraZeneca’s new engine for growth and innovation

To conclude, there is no doubt that the US, Europe and Japan remain the lead launch markets.

Encouraging data for Roche flu drug ahead of FDA decision

Discovered and developed by Shionogi, the drug is already approved in Japan and marketed as Xofluza, with Roche holding the marketing rights  outside Japan and Taiwan.

GSK to reverse ‘no KOLs’ policy, admitting it has hit marketing

The changes will be applied first to select products in the US and Japan from this month, then rolled out to Europe, North America and Asia from 2019 if it proves

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]